An Thought Leaders Invited Review published today in Genomic Psychiatry by Dr. Peng Lei and colleagues presents a sweeping ...

Data from a disease model showed that HSV1 infection caused tau hyperphosphorylation, forming aggregates that trapped viral ...

A clinical diagnostics company and biotech firm have announced a partnership to develop a blood-based tau pathology test that would assist in the diagnosis of Alzheimer’s disease. In a press release, ...

Alzheimer's disease (AD) is a neurodegenerative condition characterized by the progressive deterioration of brain cells, which prompts memory loss, a decline in mental functions and behavioral changes ...

First-in-class blood-based assay is designed to precisely detect tau pathology and to characterize Alzheimer’s disease progression in symptomatic and presymptomatic patients AUSTIN, Texas & MALVERN, ...

A biomarker test identified tau pathology in Alzheimer's disease before fibrillary tangles developed. Neurofibrillary tangle formation can be prevented by targeting intermediate soluble tau assemblies ...

Enhanced glucose uptake in glial cells might help fight AD. In Alzheimer’s disease and related neurodegenerative diseases, excess activation of glial cells causes neuroinflammation and damage to ...

A new study has somewhat redeemed the tau protein, which up to now has been associated with the development of Alzheimer’s disease. Turns out, the protein has a ‘good guy’ role, helping to protect ...

New research published in the journal Disease Models & Mechanisms offers insights into how glial cells — the supportive cells of the nervous system — may influence the progression of Alzheimer’s ...

ST. LOUIS--(BUSINESS WIRE)--C2N Diagnostics, LLC (C2N), a world leader in developing Alzheimer’s disease-specific fluid biomarker tests, has received a new $15 million program-related investment from ...